CCDC92

Summary

CCDC92 (coiled-coil domain containing 92, HGNC:29563) is a protein-coding gene on chromosome 12q24.31, encoding Coiled-coil domain-containing protein 92 (Q53HC0). Interferon-stimulated protein that plays a role in innate immunity.

Enables identical protein binding activity. Predicted to be involved in innate immune response and regulation of defense response to virus. Located in centriole; centrosome; and nucleoplasm.

Source: NCBI Gene 80212 — RefSeq curated summary.

At a glance

• GWAS associations: 78
• Clinical variants (ClinVar): 68 total
• MANE Select transcript: NM_025140

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29563
Approved symbol	CCDC92
Name	coiled-coil domain containing 92
Location	12q24.31
Locus type	gene with protein product
Status	Approved
Aliases	FLJ22471
Ensembl gene	ENSG00000119242
Ensembl biotype	protein_coding
Entrez	80212

Gene structure

Transcript identifiers

Ensembl transcripts: 57 — 55 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000238156, ENST00000535556, ENST00000539551, ENST00000539761, ENST00000542348, ENST00000544798, ENST00000545037, ENST00000545135, ENST00000545891, ENST00000902169, ENST00000902170, ENST00000902171, ENST00000902172, ENST00000902173, ENST00000902174, ENST00000902175, ENST00000902176, ENST00000902177, ENST00000902178, ENST00000902179, ENST00000902180, ENST00000902181, ENST00000902182, ENST00000902183, ENST00000902184, ENST00000902185, ENST00000902186, ENST00000902187, ENST00000902188, ENST00000902189, ENST00000902190, ENST00000902191, ENST00000902192, ENST00000902193, ENST00000902194, ENST00000902195, ENST00000902196, ENST00000963301, ENST00000963302, ENST00000963303, ENST00000963304, ENST00000963305, ENST00000963306, ENST00000963307, ENST00000963308, ENST00000963309, ENST00000963310, ENST00000963311, ENST00000963312, ENST00000963313, ENST00000963314, ENST00000963315, ENST00000963316, ENST00000963317, ENST00000963318, ENST00000963319, ENST00000963320

RefSeq mRNA: 6 — MANE Select: NM_025140 NM_001304957, NM_001304958, NM_001304959, NM_001304960, NM_001304961, NM_025140

CCDS: CCDS76619, CCDS9256

Canonical transcript exons

ENST00000238156 — 5 exons

Exon	Start	End
ENSE00001151387	123944272	123944364
ENSE00002213553	123935626	123937830
ENSE00002279623	123972529	123972831
ENSE00003526279	123943347	123943493
ENSE00003640703	123942744	123942785

Expression profiles

Bgee: expression breadth ubiquitous, 139 present calls, max score 97.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.4361 / max 188.4355, expressed in 1785 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
133971	10.0510	1724
133970	5.2508	1612
133969	1.6722	982
133966	1.1942	702
133972	1.1873	809
133975	0.4525	145
133977	0.4088	147
133976	0.3892	135
133968	0.3091	136
133967	0.2963	130

Top tissues by expression

139 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
anterior cingulate cortex	UBERON:0009835	97.81	gold quality
amygdala	UBERON:0001876	97.66	gold quality
temporal lobe	UBERON:0001871	97.65	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.64	gold quality
Ammon’s horn	UBERON:0001954	97.62	gold quality
primary visual cortex	UBERON:0002436	97.62	gold quality
superior frontal gyrus	UBERON:0002661	97.59	gold quality
right frontal lobe	UBERON:0002810	97.47	gold quality
cerebral cortex	UBERON:0000956	97.40	gold quality
frontal cortex	UBERON:0001870	97.40	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.40	gold quality
prefrontal cortex	UBERON:0000451	97.34	gold quality
hypothalamus	UBERON:0001898	97.25	gold quality
telencephalon	UBERON:0001893	97.03	gold quality
substantia nigra	UBERON:0002038	96.88	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.77	gold quality
putamen	UBERON:0001874	96.69	gold quality
apex of heart	UBERON:0002098	96.69	gold quality
nucleus accumbens	UBERON:0001882	96.64	gold quality
brain	UBERON:0000955	96.43	gold quality
caudate nucleus	UBERON:0001873	96.42	gold quality
left testis	UBERON:0004533	95.73	gold quality
heart left ventricle	UBERON:0002084	95.56	gold quality
right testis	UBERON:0004534	95.56	gold quality
popliteal artery	UBERON:0002250	95.03	gold quality
tibial artery	UBERON:0007610	95.02	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.97	gold quality
thoracic aorta	UBERON:0001515	94.94	gold quality
descending thoracic aorta	UBERON:0002345	94.94	gold quality
right coronary artery	UBERON:0001625	94.92	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting CCDC92, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4517	99.76	69.19	1867
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-142-5P	99.48	70.92	2416
HSA-MIR-5590-3P	99.48	70.91	2429
HSA-MIR-302A-5P	99.39	68.21	1913
HSA-MIR-1261	98.62	68.10	896
HSA-MIR-5089-5P	98.45	66.06	1388
HSA-MIR-3650	97.88	64.89	693
HSA-MIR-1279	97.83	67.50	1898
HSA-MIR-450B-3P	97.56	66.12	512
HSA-MIR-4642	97.52	67.60	916
HSA-MIR-769-3P	97.06	64.83	464
HSA-MIR-3616-3P	96.96	65.45	983

Literature-anchored findings (GeneRIF, showing 4)

• Mutation in CCDC92 gene is associated with insulin-resistant cardiometabolic disease. (PMID:27841877)
• Phenome-wide association scanning showed that CCDC92 likely affects coronary artery disease through insulin resistance pathways, whereas experimental analysis suggests that ARHGEF26 influences the transendothelial migration of leukocytes. (PMID:28714974)
• The genotypic and allelic frequencies of the rs11057401 SNP of CCDC92 gene were significantly different between the patients with coronary heart disease and controls. (PMID:29439709)
• Novel genetic variants of CCDC92 were associated with both Diabetes and Coronary Artery Disease . (PMID:29731020)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccdc92	ENSDARG00000041750
mus_musculus	Ccdc92	ENSMUSG00000037979
rattus_norvegicus	Ccdc92	ENSRNOG00000021691

Paralogs (1): CCDC92B (ENSG00000277200)

Protein

Protein identifiers

Coiled-coil domain-containing protein 92 — Q53HC0 (reviewed: Q53HC0)

Alternative names: Limkain beta-2

All UniProt accessions (5): Q53HC0, F5GXK2, F5H285, F5H2Z7, F5H7P8

UniProt curated annotations — full annotation on UniProt →

Function. Interferon-stimulated protein that plays a role in innate immunity. Strongly inhibits ebolavirus transcription and replication. Forms a complex with viral RNA-bound nucleocapsid NP and thereby prevents the transport of NP to the cell surface.

Subunit / interactions. Interacts with CEP164. (Microbial infection) Interacts with ebolavirus protein NP; this interaction sequesters NP in the cytoplasm.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Centriole.

Post-translational modifications. Phosphorylated at Ser-209 by TTBK2.

Induction. Up to threefold after interferon treatment.

Isoforms (2)

UniProt ID	Names	Canonical?
Q53HC0-1	1	yes
Q53HC0-2	2

RefSeq proteins (6): NP_001291886, NP_001291887, NP_001291888, NP_001291889, NP_001291890, NP_079416* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR039496	CCDC92/74_N	Domain
IPR040370	CCDC74A/CCDC74B/CCDC92	Family

Pfam: PF14916

UniProt features (11 total): sequence variant 3, coiled-coil region 2, compositionally biased region 2, chain 1, region of interest 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q53HC0-F1	73.80	0.41

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 209

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 189 (showing top): GCM_MAP4K4, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_INFLAMMATORY_RESPONSE, GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, RORA1_01, TGACCTY_ERR1_Q2, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_WOUND_HEALING, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_LEUKOCYTE_MIGRATION, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM

GO Biological Process (3): innate immune response (GO:0045087), regulation of defense response to virus (GO:0050688), immune system process (GO:0002376)

GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (5): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), centrosome (GO:0005813), centriole (GO:0005814), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
microtubule organizing center	2
intracellular membraneless organelle	2
immune response	1
defense response to symbiont	1
regulation of response to biotic stimulus	1
regulation of defense response	1
regulation of response to external stimulus	1
defense response to virus	1
biological_process	1
protein binding	1
binding	1
nuclear lumen	1
intracellular anatomical structure	1
centriole	1

Protein interactions and networks

STRING

756 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC92	ZNF664	Q8N3J9	797
CCDC92	DNAH10	Q8IVF4	787
CCDC92	SEC16B	Q96JE7	607
CCDC92	CFAP184	Q2M329	540
CCDC92	CCDC125	Q86Z20	526
CCDC92	CCDC70	Q6NSX1	506
CCDC92	TTC39A	Q5SRH9	499
CCDC92	CFAP263	Q9H0I3	488
CCDC92	CUX2	O14529	477
CCDC92	TMEM132D	Q14C87	461
CCDC92	ZCCHC8	Q6NZY4	459
CCDC92	SH2B3	Q9UQQ2	458
CCDC92	CMTR1	Q8N1G2	442
CCDC92	CCDC74B	Q96LY2	441
CCDC92	ANAPC7	Q9UJX3	437

IntAct

74 interactions, top by confidence:

A	B	Type	Score
UCHL5	PSMD11	psi-mi:“MI:0914”(association)	0.840
FHL2	CCDC92	psi-mi:“MI:0915”(physical association)	0.780
CCDC92	FHL2	psi-mi:“MI:0915”(physical association)	0.780
CCDC92	TRIML2	psi-mi:“MI:0915”(physical association)	0.740
CEP164	CCDC92	psi-mi:“MI:0915”(physical association)	0.600
CCDC92	CEP164	psi-mi:“MI:0915”(physical association)	0.600
CCDC92	CEP164	psi-mi:“MI:0403”(colocalization)	0.600
TRIM27	CCDC92	psi-mi:“MI:0915”(physical association)	0.560
CCDC92	TP53BP2	psi-mi:“MI:0915”(physical association)	0.560
CCDC92	CEP76	psi-mi:“MI:0915”(physical association)	0.560
CCDC92	TRIM27	psi-mi:“MI:0915”(physical association)	0.560
TP53BP2	CCDC92	psi-mi:“MI:0915”(physical association)	0.560
CEP76	CCDC92	psi-mi:“MI:0915”(physical association)	0.560
CCDC92	YAF9	psi-mi:“MI:0915”(physical association)	0.560
YAF9	CCDC92	psi-mi:“MI:0915”(physical association)	0.560
CCDC92	DISC1	psi-mi:“MI:0915”(physical association)	0.560
CCDC92	CCDC92	psi-mi:“MI:0915”(physical association)	0.560
tax	CCDC92	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (104): CCDC92 (Two-hybrid), CCDC92 (Two-hybrid), CCDC92 (Two-hybrid), CCDC92 (Two-hybrid), CCDC92 (Affinity Capture-MS), PSMD13 (Affinity Capture-MS), PSMD3 (Affinity Capture-MS), PSMD11 (Affinity Capture-MS), PSMC6 (Affinity Capture-MS), PSMC3 (Affinity Capture-MS), PSMC4 (Affinity Capture-MS), PSMC1 (Affinity Capture-MS), PSMC5 (Affinity Capture-MS), PSMD2 (Affinity Capture-MS), PSMD14 (Affinity Capture-MS)

ESM2 similar proteins: A0M8S4, A0M8T5, A1X157, B9EJA2, O35867, P0C6C1, P39880, P53564, P53565, Q00PJ1, Q02225, Q07DV1, Q07DW4, Q07DX4, Q07DY4, Q07DZ5, Q07E15, Q07E28, Q07E41, Q09YG9, Q09YI1, Q09YJ3, Q09YK4, Q09YM8, Q108T9, Q13625, Q2IBA2, Q2IBB2, Q2IBD4, Q2IBE6, Q2IBF7, Q2IBF8, Q2QL82, Q2QLA2, Q2QLB3, Q2QLF8, Q2QLG9, Q53HC0, Q5RDH2, Q5T1M5

Diamond homologs: Q53HC0, Q8VDN4, A0A8I5KY20

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 37 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
cilium assembly	5	12.3×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

68 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4183 predictions. Top by Δscore:

Variant	Effect	Δscore
12:123918671:TTCA:T	acceptor_loss	1.0000
12:123918673:CA:C	acceptor_loss	1.0000
12:123918674:A:AC	acceptor_loss	1.0000
12:123918945:CACAG:C	donor_loss	1.0000
12:123918946:ACAG:A	donor_loss	1.0000
12:123918947:CAGG:C	donor_loss	1.0000
12:123918948:AGG:A	donor_loss	1.0000
12:123918949:GGTGA:G	donor_loss	1.0000
12:123918951:T:G	donor_loss	1.0000
12:123923863:AAAAG:A	donor_loss	1.0000
12:123923864:AAAG:A	donor_loss	1.0000
12:123923865:AAG:A	donor_loss	1.0000
12:123923866:AGGTA:A	donor_loss	1.0000
12:123923867:GG:G	donor_loss	1.0000
12:123923868:G:C	donor_loss	1.0000
12:123923869:T:G	donor_loss	1.0000
12:123925046:CCAG:C	acceptor_loss	1.0000
12:123925047:CAGT:C	acceptor_loss	1.0000
12:123925048:A:AG	acceptor_gain	1.0000
12:123925048:A:T	acceptor_loss	1.0000
12:123925048:AGT:A	acceptor_gain	1.0000
12:123925048:AGTG:A	acceptor_gain	1.0000
12:123925049:G:GA	acceptor_gain	1.0000
12:123925049:GTG:G	acceptor_gain	1.0000
12:123925049:GTGG:G	acceptor_gain	1.0000
12:123925200:GAGAA:G	donor_gain	1.0000
12:123925202:GAA:G	donor_gain	1.0000
12:123925203:AA:A	donor_gain	1.0000
12:123925203:AAGT:A	donor_loss	1.0000
12:123925204:AG:A	donor_loss	1.0000

AlphaMissense

2158 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:123937316:A:C	F246L	0.999
12:123937316:A:T	F246L	0.999
12:123937318:A:G	F246L	0.999
12:123937581:A:G	L158P	0.999
12:123943364:A:G	L55P	0.999
12:123943385:A:G	L48P	0.998
12:123943394:A:G	L45P	0.998
12:123943420:G:C	F36L	0.998
12:123943420:G:T	F36L	0.998
12:123943422:A:G	F36L	0.998
12:123943427:A:G	L34P	0.998
12:123937317:A:C	F246C	0.997
12:123937317:A:G	F246S	0.997
12:123937569:A:G	L162P	0.997
12:123937653:A:G	L134P	0.997
12:123942770:A:G	L66P	0.997
12:123943404:C:G	A42P	0.997
12:123943418:A:G	L37P	0.997
12:123937611:A:G	L148P	0.996
12:123943361:T:G	Q56P	0.996
12:123943394:A:T	L45H	0.996
12:123937600:C:G	A152P	0.994
12:123937602:C:G	R151P	0.994
12:123943421:A:G	F36S	0.994
12:123943448:A:G	L27P	0.994
12:123937326:G:T	P243H	0.993
12:123937329:T:C	D242G	0.993
12:123943406:T:G	H41P	0.992
12:123943421:A:C	F36C	0.992
12:123943440:C:G	A30P	0.992

dbSNP variants (sampled 300 via entrez): RS1000003607 (12:123937694 C>T), RS1000089831 (12:123938910 C>A,T), RS1000176913 (12:123957649 T>C), RS1000246229 (12:123963021 C>T), RS1000351428 (12:123973221 TC>T,TCC), RS1000413378 (12:123948242 T>C), RS1000445188 (12:123969164 C>A), RS1000448375 (12:123946261 C>A), RS1000569337 (12:123942173 G>A), RS1000583565 (12:123945914 C>T), RS1000694004 (12:123947145 C>A), RS1000698711 (12:123951261 A>G), RS1000699375 (12:123947340 G>A), RS1000782513 (12:123962858 T>A), RS1000980147 (12:123935225 G>A,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

78 associations (top):

Study	Trait	p-value
GCST000755_47	HDL cholesterol	3.000000e-10
GCST000758_20	Triglycerides	1.000000e-08
GCST002782_143	Waist-to-hip ratio adjusted for body mass index	1.000000e-14
GCST002782_144	Waist-to-hip ratio adjusted for body mass index	2.000000e-15
GCST002782_145	Waist-to-hip ratio adjusted for body mass index	4.000000e-15
GCST002782_146	Waist-to-hip ratio adjusted for body mass index	2.000000e-16
GCST004505_21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)	4.000000e-17
GCST004505_22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)	1.000000e-13
GCST004507_18	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)	2.000000e-07
GCST004507_35	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)	1.000000e-07
GCST004508_37	Waist-to-hip ratio adjusted for BMI in non-smokers	3.000000e-08
GCST004508_38	Waist-to-hip ratio adjusted for BMI in non-smokers	1.000000e-07
GCST004563_129	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	7.000000e-10
GCST004563_208	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	2.000000e-16
GCST004564_69	Waist circumference adjusted for BMI in active individuals	4.000000e-17
GCST004564_70	Waist circumference adjusted for BMI in active individuals	8.000000e-11
GCST004567_104	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	3.000000e-19
GCST004567_118	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	4.000000e-18
GCST004567_12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	3.000000e-18
GCST004567_31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	4.000000e-18
GCST004576_1	Waist-to-hip ratio adjusted for body mass index	5.000000e-18
GCST004576_11	Waist-to-hip ratio adjusted for body mass index	8.000000e-17
GCST004576_12	Waist-to-hip ratio adjusted for body mass index	1.000000e-19
GCST004576_13	Waist-to-hip ratio adjusted for body mass index	8.000000e-21
GCST004578_140	Waist-to-hip ratio adjusted for BMI in active individuals	6.000000e-19
GCST004578_44	Waist-to-hip ratio adjusted for BMI in active individuals	3.000000e-18
GCST004578_59	Waist-to-hip ratio adjusted for BMI in active individuals	1.000000e-19
GCST004578_82	Waist-to-hip ratio adjusted for BMI in active individuals	4.000000e-18
GCST004610_133	White blood cell count	3.000000e-09
GCST004622_124	Reticulocyte count	6.000000e-09

EFO canonical traits (15, from GWAS)

EFO ID	Trait name
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004530	triglyceride measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0004318	smoking behavior
EFO:0007789	BMI-adjusted waist circumference
EFO:0008002	physical activity measurement
EFO:0007986	reticulocyte count
EFO:0006941	grip strength measurement
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0010368	lysophosphatidylethanolamine 18:1 measurement
EFO:0008039	BMI-adjusted hip circumference
EFO:0004531	urate measurement
EFO:0004587	lymphocyte count
EFO:0004305	erythrocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases methylation, affects expression, increases expression	4
Benzo(a)pyrene	affects methylation, increases expression	3
sodium arsenite	affects cotreatment, increases abundance, decreases expression	2
entinostat	decreases expression, increases expression, affects cotreatment	2
(+)-JQ1 compound	increases expression	2
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	increases methylation	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
benzo(e)pyrene	decreases methylation	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
azoxystrobin	decreases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Acetaminophen	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Atrazine	decreases expression	1
Cadmium	decreases expression, increases abundance	1
Copper	affects binding, increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B5JS	HAP1 CCDC92 (-) 2	Cancer cell line	Male
CVCL_B5JT	HAP1 CCDC92 (-) 3	Cancer cell line	Male
CVCL_XM51	HAP1 CCDC92 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.